Interestingly, it has been previously shown that cisplatin enhances the secretion of TGF-β1, which may lead to mesenchymal-like phenotypic changes and the subsequent development of cisplatin resistance in NSCLC [63]. The gene discussed is TGFB1; the disease is non-small cell lung carcinoma.